This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kyowa Hakko Kirin Co., Ltd.
Drug Names(s): KW-2450
Description: KW-2450 was originally developed by Kyowa Hakko Kirin.
KW-2450 is a small molecule insulin-like growth factor receptor (IGF-1R)/insulin receptor (IR) antagonist. It selectively binds to and inhibits the activities of both IGF-1R and IR, possibly resulting in the inhibition of tumour cell proliferation and induction of tumour cell apoptosis.
Additional information available to subscribers only: